Clinical Trials

Haisco's Cipepofol gains US FDA approval, challenging Propofol with enhanced safety and signaling a new era of Chinese pharmaceutical innovation.

With over 7 million Americans facing Alzheimer's, an innovative online study empowers you to monitor your brain health and join the fight from home.

With strong data for volixibat, brelovitug, and LIVMARLI, Mirum (MIRM) de-risks its pipeline and sets the stage for growth. Here's the analysis.

Landmark Phase 3 trial shows TECVAYLI dramatically improves survival in early relapse, poised to become a new standard of care for multiple myeloma.

With a new CMO who has a drug approval under his belt, ImmunoGenesis is poised to advance its novel therapy for hard-to-treat 'cold' tumors.

A novel oncolytic bacteria therapy gains key approvals in the US and China, showcasing a new global development model enabled by CDMO Porton Advanced.

A novel drug aims to starve deadly brain tumors by rewiring their metabolism. BPGbio's upcoming ASCO update could signal a major shift for glioblastoma.

Clymb Clinical's new Data Mapper uses AI to automate complex data mapping, promising to accelerate drug trials and redefine statistical programming roles.

PeproMene Bio’s PMB-CT01 offers new hope, achieving a 78% complete response rate with a remarkable safety profile in hard-to-treat lymphoma patients.

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

With late-stage trials for its revolutionary eye and lung disease treatments, 4DMT must convince investors its focused, high-stakes strategy will pay off.

Summit and Pinnacle unite to create a seamless clinical research platform, promising to accelerate drug development and boost trial efficiency. Here's what it means.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

Positive Phase 3 data for oral drug filgotinib offers new hope for thousands of axial spondyloarthritis patients who fail to respond to current therapies.

A new global repository by Zifo and the Pistoia Alliance aims to standardize biological data, promising to accelerate drug discovery and fix costly data silos.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.